无论指征如何,腺瘤检出率与筛查腺瘤检出率相当:对质量监测的意义
该研究回顾了2015年6个月内两家退伍军人事务中心21名内镜医师的连续结肠镜检查,计算筛查、非筛查及所有指征的腺瘤检出率(ADR),并进行模拟建模。结论提示无论指征评估ADR可能足以用于质量监测。
要点
- 监测和诊断检查的ADR分别为56%和38%。
- 模拟建模中16种情景仅1种显示筛查与非筛查ADR有显著差异。
核心结论
- 所有结肠镜检查计算的总体ADR与基于筛查结肠镜的传统ADR无显著差异。
- 无论指征评估ADR可能足以用于质量监测,并促进质量测量与报告的实施。
研究设计与样本
- 回顾性队列研究,纳入两家退伍军人事务中心21名内镜医师2015年6个月内的连续结肠镜检查。
- 共分析2628例结肠镜检查,并进行模拟建模(100,000次试验,每次3000名参与者)。
主要发现
- 筛查指征占28.9%,监测指征占48.2%,诊断指征占22.9%。
- 监测检查的ADR为56%,诊断检查的ADR为38%。
- 模拟建模中,16种情景仅1种(筛查10%、监测70%、诊断10%、FIT+10%)显示筛查与非筛查指征的ADR有显著差异。
临床怎么用
- 可考虑使用所有结肠镜检查(无论指征)的ADR进行质量监测,以简化质量测量和报告。
- 在临床实践中采用该方法前,需在其他地区进行前瞻性研究验证其有效性。
局限性
- 研究仅纳入退伍军人事务中心人群,结果外推需谨慎。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Adenoma detection rate (ADR) is a key measure of colonoscopy quality. However, efficient measurement of ADR can be challenging because many colonoscopies are performed for non-screening purposes. Measuring ADR without being restricted to screening indication may likely facilitate more widespread implementation of quality monitoring. We hypothesized that the ADR for all colonoscopies, irrespective of the indication, would be equivalent to the ADR for screening colonoscopies. METHODS: We reviewed consecutive colonoscopies at two Veterans Affairs centers performed by 21 endoscopists over 6 months in 2015. We calculated the ADR for screening exams, non-screening (surveillance and diagnostic) exams, and all exams (irrespective of indication), correcting for within-endoscopist correlation. We then performed simulation modeling to calculate the ADRs under 16 hypothetical scenarios of various indication distributions. We simulated 100,000 trials with 3,000 participants, randomly assigned indication (screening, surveillance, diagnostic, and FIT+) from a multinomial distribution, randomly drew adenoma using the observed ADRs per indication, and calculated 95% confidence intervals of the mean differences in ADR of screening and non-screening indications. RESULTS: Among 2628 colonoscopies performed by 21 gastroenterologists, the indication was screening in 28.9%, surveillance in 48.2% and diagnostic in 22.9%. There was no significant difference in the ADR, 50% (95%CI: 45-56%) for all colonoscopies vs 49% (95%CI: 43-56%) for screening exams (p=.55). ADRs were 56% for surveillance and 38% for diagnostic exams. In our simulation modeling, only one out of 16 scenarios (screening 10%, surveillance 70%, diagnostic 10% and FIT+ 10%) resulted in a significant difference between the calculated ADRs for screening and non-screening indications. CONCLUSIONS: In our study, the overall ADR computed from all colonoscopies was not significantly different than the conventional ADR based on screening colonoscopies. Assessing ADR for colonoscopy irrespective of indication may be adequate for quality monitoring, and could facilitate the implementation of quality measurement and reporting. Future prospective studies should evaluate the validity of using overall ADR for quality reporting in other jurisdictions before adopting this method in clinical practice.
引用
- Kaltenbach T, Gawron A, Meyer CS, et al. Adenoma Detection Rate (ADR) Irrespective of Indication Is Comparable to Screening ADR: Implications for Quality Monitoring. Clin Gastroenterol Hepatol. 2021. PMID: 33618027. doi:10.1016/j.cgh.2021.02.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。